NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive top-line safety and immunogenicity results from substudy B of the ongoing pivotal Phase 3 clinical trial (NCT05842967) MONeT ...
Respiratory syncytial virus is continuing to spread later into the spring than usual, driving most states to extend the window for RSV immunizations for eligible infants and toddlers. RSV is a common ...
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants. The US Food and Drug Administration ...
Influenza and other respiratory viruses are starting to circulate but so far remain lower than this time last year, according to the Centers for Disease Control and Prevention. As of Oct. 7, CDC's ...
Please provide your email address to receive an email when new articles are posted on . GSK’s Arexvy became the third RSV vaccine approved for high-risk adults aged younger than 50 years. The CDC has ...
Although cold and flu season is winding down in the United States, respiratory syncytial virus (RSV) activity still remains high in many parts of the country. RSV is a highly contagious virus that can ...
If your patient is pregnant or older than 60 years and due for a respiratory syncytial virus (RSV) shot, now’s the time to act. A major new review highlighted the vaccine’s impact and safety, ...
Guillain-Barré syndrome (GBS) cases following respiratory syncytial virus (RSV) vaccination in adults 60 and up appeared slightly elevated compared with expected rates, though on the population level ...
Share on Pinterest RSV infection can become serious in infants and young children, but there are ways to protect against severe illness. MaaHoo/Stocksy Respiratory syncytial virus (RSV) is a common ...
Respiratory syncytial virus (RSV) is an infection that affects your lungs, nose, throat, and breathing passages. You get it when infected droplets enter your nose, eyes, or mouth. This might happen ...
For older adults, the vaccine against respiratory syncytial virus (RSV) appears to be most effective in the first year after administration, according to new research that shows the benefits of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results